Navigation Links
First dual-action compound kills cancer cells, stops them from spreading

Scientists are reporting development and successful lab tests on the first potential drug to pack a lethal one-two punch against melanoma skin cancer cells. Hit number one destroys cells in the main tumor, and the second hit blocks the spread of the cancer to other sites in the body, according to their report in the journal ACS Chemical Biology.

Nathan Luedtke and colleagues explain that the spread of melanoma and other forms of cancer beyond the original location a process called metastasis makes cancer such a serious disease. Photodynamic therapy (PDT), which involves administering a drug that kills cancer cells when exposed to light, already is available. But PDT works only on the main tumor and has other drawbacks. Luedtke's team set out to find an improved approach to PDT.

The scientists describe successful tests in laboratory mice of one compound they synthesized that not only killed melanoma cells, but also stopped them from metastasizing by blocking a key signal inside the tumor cells. The compound "provides the first example of a preclinical candidate possessing both of these properties," the scientists state.


Contact: Michael Bernstein
American Chemical Society

Page: 1

Related biology news :

1. Kessler Foundation implements Ekso Bionics first commercial robotic exoskeleton
2. Research reveals first evidence of hunting by prehistoric Ohioans
3. First model of how buds grow into leaves
4. American College of Rheumatology releases first classification criteria for polymyalagia rheumatica
5. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
6. First complete full genetic map of promising energy crop
7. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
8. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
9. New technology tracks sparrow migration for first time from California to Alaska
10. First mass extinction linked to marine anoxia
11. Scientists complete first-ever emperor penguin count from space
Post Your Comments:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
(Date:10/27/2015)... NEW YORK , Oct. 27, 2015 ... the major issues of concern for various industry verticals ... This is due to the growing demand for secure ... practices in various ,sectors, such as hacking of bank ... concerns for electronic equipment such as PC,s, laptops, and ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology: